{
    "root": "30db4678-f085-d335-e063-6394a90a646e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Enalapril maleate",
    "value": "20250321",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01390"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "ENALAPRIL MALEATE",
            "code": "9O25354EPJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4785"
        }
    ],
    "indications": {
        "text": "hypertension enalapril maleate tablets usp indicated treatment hypertension . enalapril maleate tablets usp effective alone combination antihypertensive agents , especially thiazide- type diuretics . blood pressure lowering effects enalapril maleate tablets usp thiazides approximately additive . heart failure enalapril maleate tablets usp indicated treatment symptomatic congestive heart failure , usually combination diuretics digitalis . patients enalapril maleate tablets usp improves symptoms , increases survival , decreases frequency hospitalization ( pharmacology , heart failure , mortality trialsfor details limitations survival trials ) . asymptomatic left ventricular dysfunction clinically stable asymptomatic patients left ventricular dysfunction ( ejection fraction \u226435 percent ) , enalapril maleate tablets usp decreases rate development overt heart failure decreases incidence hospitalization heart failure ( pharmacology , heart failure , mortality trialsfor details limitations survival trials ) . using enalapril maleate tablets usp consideration given fact another angiotensin converting enzyme inhibitor , captopril , caused agranulocytosis , particularly patients renal impairment collagen vascular disease , available data insufficient show enalapril maleate tablets usp similar risk ( , neutropenia/agranulocytosis ) . considering enalapril maleate tablets usp , noted controlled trials ace inhibitors effect blood pressure less black patients non-blacks . addition , noted black patients receiving ace inhibitors reported higher incidence angioedema compared non-blacks ( , head neck angioedema ) .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "congestive heart failure (DOID:6000)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6000"
            },
            {
                "text": "agranulocytosis (DOID:12987)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12987"
            },
            {
                "text": "vascular disease (DOID:178)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_178"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "angioedema (DOID:1558)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1558"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": null,
    "warningsAndPrecautions": "enalapril maleate tablets usp , 20 mg available peach , oval , convex tablets debossed `` 707 `` one side bisect side . supplied follows : ndc : 70518-4153-00 ndc : 70518-4153-01 packaging : 90 1 bottle plastic packaging : 100 1 bottle plastic storage store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . keep container tightly closed . protect moisture . dispense tight container per usp , product package subdivided . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "enalapril maleate contraindicated patients hypersensitive product patients history angioedema related previous treatment angiotensin-converting enzyme inhibitor patients hereditary idiopathic angioedema . coadminister aliskiren enalapril maleate patients diabetes ( , ) . enalapril maleate contraindicated combination neprilysin inhibitor ( e.g . , sacubitril ) . administer enalapril maleate within 36 hours switching sacubitril/valsartan , neprilysin inhibitor ( , head neck angioedema ) .",
    "indications_original": "Hypertension\n                  \n                  Enalapril maleate tablets USP are indicated for the treatment of hypertension.\n                  Enalapril maleate tablets USP are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of enalapril maleate tablets USP and thiazides are approximately additive.\n                  \n                     Heart Failure\n                  \n                  Enalapril maleate tablets USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets USP improves symptoms, increases survival, and decreases the frequency of hospitalization (see\n \n  CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trialsfor details and limitations of survival trials).\n\n \n                  \n                     Asymptomatic Left Ventricular Dysfunction\n                  \n                  In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction \u226435 percent), enalapril maleate tablets USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see\n \n  CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trialsfor details and limitations of survival trials).\n\n \n                  In using enalapril maleate tablets USP consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets USP does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis).\n                  In considering use of enalapril maleate tablets USP, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see\n \n  WARNINGS, Head and Neck Angioedema).",
    "warningsAndPrecautions_original": "Enalapril maleate tablets USP, 20 mg are available as peach, oval, convex tablets debossed \"707\" on one side and bisect on the other side.\n                  They are supplied as follows:\n                  \n                  NDC: 70518-4153-00\n                  NDC: 70518-4153-01\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 100 in 1 BOTTLE PLASTIC\n                  \n                  \n                  Storage\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Keep container tightly closed. Protect from moisture.\n                  Dispense in a tight container as per USP, if product package is subdivided.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.\n                  Do not coadminister aliskiren with enalapril maleate in patients with diabetes (see\n \n  PRECAUTIONS, Drug Interactions).\n\n \n                  Enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see\n \n  WARNINGS, Head and Neck Angioedema).",
    "drug": [
        {
            "name": "Enalapril maleate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4785"
        }
    ]
}